Who We Are
Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015.
Our first product is lixivaptan, in Phase 3 development for the treatment of ADPKD. There is currently only one approved product available for the more than 140,000 patients diagnosed with ADPKD in the US. The current product has been associated with liver toxicity and requires frequent blood tests to monitor for liver toxicity. We are conducting clinical trials to confirm that lixivaptan will be a safe and effective treatment for patients with ADPKD, without the liver safety issues associated with the current approved treatment.
Our mission is to develop transformative medicines for
orphan diseases of the kidney.
We are committed to making a meaningful impact on
Palladio is actively investigating the efficacy of lixivaptan as well as its potential to deliver a differentiated safety profile in terms of drug induced liver toxicity for patients with Polycystic Kidney Disease (PKD).
Lixivaptan is a new chemical entity that works by selectively suppressing the hormone vasopressin at the V2 receptor. Extensive clinical trials have proven that vasopressin V2 antagonists like lixivaptan can effectively treat ADPKD.
The development program for lixivaptan is expected to show that lixivaptan can slow the decline in renal function that is typically observed in ADPKD. We believe that early therapy initiation with a vasopressin V2 antagonist like lixivaptan could delay or possibly eliminate the need for dialysis or kidney transplant in many ADPKD patients.